-+ 0.00%
-+ 0.00%
-+ 0.00%

Pacira urges vote for board slate as activist DOMA pushes company sale at June 9 meeting

PUBT·04/28/2026 20:47:48
Listen to the news
Pacira urges vote for board slate as activist DOMA pushes company sale at June 9 meeting
  • Pacira escalated fight with activist DOMA Perpetual ahead of June 9 annual meeting, filing definitive proxy materials.
  • Board urged stockholders to back Pacira slate on blue card: Christopher Christie, Samit Hirawat, Thomas Wiggans.
  • Company opposed election of DOMA nominees, calling them underqualified with no public board or biopharma operating experience.
  • Pacira said it held 17 meetings with DOMA since September 2023.
  • Pacira highlighted capital returns, citing $150 million in 2025 buybacks plus $50 million in 2026, cutting shares outstanding to 39 million from 47 million.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pacira Biosciences Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202604281620PRIMZONEFULLFEED9708783) on April 28, 2026, and is solely responsible for the information contained therein.